CDNA CAREDX INC

CareDx to Report First Quarter 2022 Financial Results

CareDx to Report First Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the first quarter 2022 after market close on Thursday, May 5, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Individuals interested in listening to the conference call may do so by dialing 877-300-8521 for domestic callers or 412-317-6026 for international callers. Please reference Conference ID: 10165254. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: .

About CareDx – The Transplant Company

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: .

CONTACTS:

CareDx, Inc.

Investor Relations

Ian Cooney

415-287-2300 x 3550





EN
27/04/2022

Underlying

CDNACAREDX INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CAREDX INC

Free Trial
CDNA CAREDX INC

CareDx Inc: 1 director

A director at CareDx Inc sold 20,000 shares at 18.355USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

03/12/25 March 12, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 46.11
MDWD MEDIWOUND
EBS Emergent BioSol... ... (+20)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

MDWD MEDIWOUND
EBS EMERGENT BIOSOLUTIONS INC.
CDNA CAREDX INC
THS TREEHOUSE FOODS INC.
FONR FONAR CORP.
KIDS ORTHOPEDIATRICS CORP
AMD ADVANCED MICRO DEVICES INC.
KRYS KRYSTAL BIOTECH INC
MMMB MAMAMANCINI'S HOLDINGS INC
SITM SITIME
RNA AVIDITY BIOSCIENCES
PWP PERELLA WEINBERG PARTNERS
ASTS AST SPACEMOBILE INC
BRBR BELLRING BRANDS INC
INTR INTER & CO INC
EWTX EDGEWISE THERAPEUTICS INC
ACRV ACRIVON THERAPEUTICS INC
WGS GENEDX HOLDINGS CORP.
XPOF XPONENTIAL FITNESS INC
SOWG SOW GOOD INC
07/08/24 July 8, 2024 1 EN
 PRESS RELEASE
Free
CDNA CAREDX INC

CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell ...

CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell Transplantation CareDx Expands Transplant Portfolio in Europe SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) --  CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it has received CE marking for its AlloSeq HCT chimerism testing kit and AlloSeq HCT interpretation software for use in patients who have received hematopoieti...

May 24, 2022 1 EN
 PRESS RELEASE
Free
CDNA CAREDX INC

CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung...

CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung Allograft Dysfunction Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant Outcomes SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the International Society for Heart and Lung Transplantation (ISHLT) has selected Dr. Berta Sáez-Gim...

May 18, 2022 1 EN
 PRESS RELEASE
Free
CDNA CAREDX INC

In CareDx-Initiated IP Litigation Against Natera, Natera Now Drops 1 o...

In CareDx-Initiated IP Litigation Against Natera, Natera Now Drops 1 of 2 Patents Originally Asserted Against CareDx Natera Recycles Old IP for New Lawsuits SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that Natera has just dropped one of their two patents originally asserted against CareDx. At the same time, Natera asserted two patents tha...

May 17, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch